WallStSmart

Electrocore LLC (ECOR)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 118834% more annual revenue ($35.48B vs $29.84M). MDT leads profitability with a 13.0% profit margin vs -47.5%. MDT earns a higher WallStSmart Score of 56/100 (C).

ECOR

Avoid

28

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ECOR.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ECOR1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
32.6%10/10

Revenue surging 32.6% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

ECOR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$49.97M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-3.4%2/10

ROE of -3.4% — below average capital efficiency

Free Cash FlowQuality
$-1.54M2/10

Negative free cash flow — burning cash

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ECOR

The strongest argument for ECOR centers on Revenue Growth. Revenue growth of 32.6% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : ECOR

The primary concerns for ECOR are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

ECOR profiles as a hypergrowth stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.73 — expect wider price swings.

ECOR is growing revenue faster at 32.6% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 28/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Electrocore LLC

HEALTHCARE · MEDICAL DEVICES · USA

electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?